89 related articles for article (PubMed ID: 8960549)
1. Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrophostins: potent inhibitors of EGF receptor tyrosine kinase in vitro.
Gazit A; Osherov N; Gilon C; Levitzki A
J Med Chem; 1996 Dec; 39(25):4905-11. PubMed ID: 8960549
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
[TBL] [Abstract][Full Text] [Related]
4. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antiproliferative activity of tyrphostins containing quinoline moieties.
Brunton VG; Lear MJ; McKeown P; Robins DJ; Workman P
Anticancer Drug Des; 1996 Sep; 11(6):463-83. PubMed ID: 8836111
[TBL] [Abstract][Full Text] [Related]
6. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
Kamath S; Buolamwini JK
J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
[TBL] [Abstract][Full Text] [Related]
8. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors.
Han Y; Caday CG; Nanda A; Cavenee WK; Huang HJ
Cancer Res; 1996 Sep; 56(17):3859-61. PubMed ID: 8752145
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor regulates protein kinase A activity in murine fibrosarcoma cells: differences between metastatic and nonmetastatic tumor cell variants.
Fishman D; Galitzki L; Priel E; Segal S
Cancer Res; 1997 Dec; 57(23):5410-5. PubMed ID: 9393768
[TBL] [Abstract][Full Text] [Related]
15. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.
Liechti C; Séquin U; Bold G; Furet P; Meyer T; Traxler P
Eur J Med Chem; 2004 Jan; 39(1):11-26. PubMed ID: 14987830
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Thompson AM; Bridges AJ; Cody DR; Zhou H; Fry DW; McMichael A; Denny WA
J Med Chem; 1996 Apr; 39(9):1823-35. PubMed ID: 8627606
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors.
Pannala M; Kher S; Wilson N; Gaudette J; Sircar I; Zhang SH; Bakhirev A; Yang G; Yuen P; Gorcsan F; Sakurai N; Barbosa M; Cheng JF
Bioorg Med Chem Lett; 2007 Nov; 17(21):5978-82. PubMed ID: 17827009
[TBL] [Abstract][Full Text] [Related]
18. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
[TBL] [Abstract][Full Text] [Related]
19. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of a series of hydroxybenzylphenylamine derivatives as inhibitors of EGF receptor-associated tyrosine kinase activity.
Chen H; Bashiardes G; Mailliet P; Commercon A; Sounigo F; Boiziau J; Parker F; Tocque B; Roques BP; Garbay C
Anticancer Drug Des; 1996 Jan; 11(1):49-71. PubMed ID: 8639248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
